未找到相关数据
A phase II multicenter trial of the multitargeted kinase inhibitor sulfatinib in advanced medullary thyroid cancer (MTC) and radioiodine (RAI)-refractory differentiated thyroid cancer (DTC).
被引：2
作者：
Chen, Jiaying
Ji, Qinghai
Cao, Junning
Ji, Dongmei
Bai, Chunmei
Lin, Yansong
Pan, Bin
Sun, Guofang
Li, Jing
Qi, Chuan
Hua, Ye
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[2] Fudan Univ, Shanghai Canc Ctr, Dept Med Oncol, Phase Unit, Shanghai, Peoples R China
[3] Fudan Univ, Shanghai Canc Ctr, Dept Med Oncol, Shanghai, Peoples R China
[4] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Beijing, Peoples R China
[5] Peking Union Med Coll Hosp, Beijing, Peoples R China
[6] Hutchis MediPharma Ltd, Shanghai, Peoples R China
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.6037
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6037
引用
收藏
页数：5
相关论文